David Cibula
Overview
Explore the profile of David Cibula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
256
Citations
5451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vergote I, Copeland L, Van Gorp T, Laenen A, Scambia G, Thaker P, et al.
Eur J Cancer
. 2025 Feb;
219:115306.
PMID: 40010134
Purpose: Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell viability and tumor progression. The pivotal, phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 study evaluated efficacy and safety of...
2.
Trillsch F, Czogalla B, Mahner S, Loidl V, Reuss A, du Bois A, et al.
Int J Surg
. 2025 Feb;
PMID: 39992106
Background: Anastomotic leakage is a significant complication following bowel resection in cytoreductive surgery for ovarian cancer. Previous studies have highlighted the detrimental effects of anastomotic leakage on patients' postoperative course....
3.
Stukan M, Jedryka M, Cokan A, Klat J, Ndukwe M, Kryszpin M, et al.
Support Care Cancer
. 2025 Feb;
33(3):202.
PMID: 39969588
Malignant ascites (MA) and repeated paracentesis can impair a patient's quality of life (QOL). The aim was to perform an interim analysis of safety and changes in patients' QOL in...
4.
Dundr P, Hojny J, Dvorak J, Hajkova N, Vrankova R, Krkavcova E, et al.
Lab Invest
. 2025 Feb;
105(5):104092.
PMID: 39921027
The Rare Gynecologic Sarcoma study involved 23 institutions from 10 countries focusing on myxoid leiomyosarcoma and non-smooth muscle uterine sarcomas. Here, we present the main results of the study, including...
5.
Oza A, Lisyanskaya A, Fedenko A, de Melo A, Shparyk Y, Rakhmatullina I, et al.
Lancet Oncol
. 2025 Feb;
26(2):249-264.
PMID: 39914419
Background: In the ARIEL4 trial of rucaparib versus standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma, the primary endpoint was met, showing improved investigator-assessed progression-free survival with rucaparib. Here,...
6.
Flidrova M, Dundr P, Vrankova R, Nemejcova K, Cibula D, Poncova R, et al.
Virchows Arch
. 2025 Jan;
PMID: 39836188
Low-grade endometrial stromal sarcoma (LG-ESS) can present diagnostic challenges, due to its overlapping morphological features with other uterine mesenchymal tumors. Misdiagnosis rates remain significant, and immunohistochemical data for LG-ESS are...
7.
Scambia G, Villalobos Valencia R, Colombo N, Cibula D, Leath 3rd C, Bidzinski M, et al.
J Clin Oncol
. 2024 Dec;
:JCO2400933.
PMID: 39668137
Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer in the open-label phase III SOLO3...
8.
Dundr P, Dvorak J, Krausova M, Hojny J, Hajkova N, Struzinska I, et al.
Virchows Arch
. 2024 Dec;
PMID: 39627614
Uterine sarcomas with KAT6B/A::KANSL1 fusion represent a new entity characterized by bland morphology, commonly with hybrid features of low-grade endometrial stromal sarcoma (LG-ESS) and tumors with smooth muscle differentiation. In...
9.
Powell M, Cibula D, OMalley D, Boere I, Shahin M, Savarese A, et al.
Gynecol Oncol
. 2024 Nov;
192():40-49.
PMID: 39531903
Objectives: Part 1 of the RUBY trial (NCT03981796) demonstrated improved survival in patients with primary advanced or recurrent endometrial cancer (EC) treated with dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel....
10.
Stolnicu S, Allison D, Tessier-Cloutier B, Momeni-Boroujeni A, Hoang L, Ieni A, et al.
Pathology
. 2024 Oct;
57(1):17-26.
PMID: 39477763
The aim of this study was to determine whether the presence and extent of lymphovascular invasion (LVI) is prognostic in surgical stage I cervical squamous cell carcinoma (SCC). All available...